parent conditions

Essential Thrombocythemia

Secondary Myelofibrosis

synonyms

Post-ET MF

Post-Essential Thrombocythemia Myelofibrosis

Myelofibrosis Transformation in Essential Thrombocythemia

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)

129 sites for NCT04551066

del(11)(q10), +27 more biomarkers

Myelofibrosis Transformation in Essential Thrombocythemia, +2 more conditions

parsaclisib, +1 more drug

targeted therapy

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304)

144 sites for NCT04551053

del(11)(q10), +27 more biomarkers

Myelofibrosis

parsaclisib, +1 more drug

targeted therapy

An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

140 sites for NCT04717414

Myelofibrosis Transformation in Essential Thrombocythemia, +2 more conditions

luspatercept

Other

A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment

143 sites for NCT04576156

del(11)(q10), +27 more biomarkers

Myelofibrosis

imetelstat, +1 more drug

targeted therapy

Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis

190 sites for NCT04468984

del(11)(q10), +27 more biomarkers

Myelofibrosis Transformation in Essential Thrombocythemia, +2 more conditions

navitoclax, +1 more drug

targeted therapy

Study of Oral Navitoclax Tablet In Combination With Oral Ruxolitinib Tablet When Compared With Oral Ruxolitinib Tablet To Assess Change In Spleen Volume In Adult Participants With Myelofibrosis

166 sites for NCT04472598

del(11)(q10), +27 more biomarkers

Myelofibrosis

navitoclax, +1 more drug

targeted therapy

lenalidomide +/- prednisone

del(5)(q31q33)

Myelofibrosis

lenalidomide, +1 more drug

chemotherapy, +1 more type

pacritinib

Primary Myelofibrosis, +1 more condition

High risk, +1 more state

pacritinib

targeted therapy

fedratinib

Primary Myelofibrosis, +1 more condition

High risk, +1 more state

fedratinib

targeted therapy

ruxolitinib

Myelofibrosis

High risk, +1 more state

ruxolitinib

targeted therapy